Mark Cuban Cost Plus Drug Company partners with SHARx
SHARx and Mark Cuban Cost Plus Drug Company are teaming up to address the specialty drug markets by offering underinsured members access to those medications at affordable prices. The agreement expands SHARx’s extensive sourcing channels, opening the catalog of medications carried by Cost Plus Drugs to SHARx members.
SHARx is a patient advocacy organization working with uninsured and underinsured Americans, providing a myriad of access options for high-cost maintenance and specialty medications for their members.
Read more: Mark Cuban Cost Plus Drug Company partners with Scripta Insights]
“High cost and Specialty medications can cost upwards of $1.5 million per year in the United States,” said Corey Durbin, CEO of SHARx. “Astronomical prices are preventing millions of Americans from accessing the lifesaving and life-altering medications they need,” he added. “This connectivity adds yet another tool SHARx can use to help members find the access they need.”
"We are thrilled to collaborate with SHARx in our mission to make prescription drugs more affordable for consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with SHARx we are dedicated to providing affordable and accessible healthcare solutions for all."
[Read more: Mark Cuban Cost Plus Drug Company partners with Sidecar Health]